Histone deacetylase 1/Sp1/MicroRNA-200b Signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Chen, Dong Qin ^a   Huang, Jia Yuan ^a   Feng, Bing ^a   Pan, Ban Zhou ^a   De, Wei ^b   Wang, Rui ^a   Chen, Long Bang ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; DOCETAXEL; EPITHELIAL CELL ADHESION MOLECULE; HISTONE DEACETYLASE 1; MICRORNA 200B; TRANSCRIPTION FACTOR SP1; UVOMORULIN; CADHERIN; HDAC1 PROTEIN, HUMAN; MESSENGER RNA; MICRORNA; MIRN200 MICRORNA, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; SP1 PROTEIN, HUMAN; SUZ12 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME MECHANISM; ENZYME REPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ADENOCARCINOMA; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION; ADENOCARCINOMA; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CADHERINS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASTIC STEM CELLS; POLYCOMB REPRESSIVE COMPLEX 2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943612034     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109578     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, et al. (2011) MicroRNA- 451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 29:1661-71.
3. Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, et al. (2013) Discrete nature of EPCAM(+) and CD90(+) cancer stem cells in human hepatocellular carcinoma. Hepatology 57:1484-97.
4. Levina V, Marrangoni A, Wang T, Parikh S, Su Y, et al. (2010) Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res 70:338-46.
5. Van den Broeck A, Vankelecom H, Van Delm W, Gremeaux L, Wouters J, et al. (2013) Human pancreatic cancer contains a side population expressing cancer stem cell-associated and prognosticgenes. Plos One 8:e73968.
6. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, et al. (2013) Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154:61-74.
7. Bu P, Chen KY, Chen JH, Wang L, Walters J, et al. (2013) A microRNA miR- 34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell 12:602-15.
8. Beck B, Driessens G, Goossens S, Youssef KK, Kuchnio A, et al. (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478:399-403.
9. Scaffidi P, Misteli T (2011) In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol 13:1051-61.
10. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138:645-59.
11. Kim IG, Kim SY, Choi SI, Lee JH, Kim KC, et al. (2014) Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling. Oncogene 33:3908-17.
12. Sarvi S, Mackinnon AC, Avlonitis N, Bradley M, Rintoul RC, et al. (2014) CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res 74:1554-65.
13. Zhao J, Ma MZ, Ren H, Liu Z, Edelman MJ, et al. (2013) Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy. Clin Cancer Res 19:3567-76.
14. White RA, Neiman JM, Reddi A, Han G, Birlea S, et al. (2013) Epithelial stem cell mutations that promote squamous cell carcinoma metastasis. J Clin Invest 123:4390-404.
15. Iliopoulos D, Hirsch HA, Struhl K (2011) Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71:3196-201.
16. Okuda H, Xing F, Pandey PR, Sharma S, Watabe M, et al. (2013) miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res 73:1434-44.
17. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, et al. (2010) Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 39:761-72.
18. Sun L, Yao Y, Liu B, Lin Z, Lin L, et al. (2012) MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 31:432-45.
19. Feng B, Wang R, Song HZ, Chen LB (2012) MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer 118:3365-76.
20. Wang R, Wang ZX, Yang JS, Pan X, De W, et al. (2011) MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 30: 2644-58.
21. Wee EJ, Peters K, Nair SS, Hulf T, Stein S, et al. (2012) Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer. Oncogene 31:4182-95.
22. Emlet DR, Gupta P, Holgado-Madruga M, Del Vecchio CA, Mitra SS, et al. (2014) Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. Cancer Res 74:1238-49.
23. Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, et al. (2012) Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149:1284-97.
24. Antoniou A, Hebrant A, Dom G, Dumont JE, Maenhaut C (2013) Cancer stem cells, a fuzzy evolving concept: A cell population or a cell property? Cell Cycle 12:3743-8.
25. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, et al. (2011) Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res 17:6934-43.
26. Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B, Nestor M (2014) Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells. Plos One 9:e94621.
27. Yang J, Liao D, Chen C, Liu Y, Chuang TH, et al. (2013) Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells 31:248-58.
28. Siemens H, Jackstadt R, Kaller M, Hermeking H (2013) Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget 4:1399-415.
29. Vazquez-Martin A, Cufi S, Lopez-Bonet E, Corominas-Faja B, Cuyas E, et al. (2013) Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells. Cell Cycle 12: 3471-7.
30. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, et al. (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138:592-603.
31. Bao B, Wang Z, Ali S, Kong D, Li Y, et al. (2011) Notch-1 induces epithelialmesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 307:26-36.
32. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, et al. (2009) miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 27:1712-21.
33. Shi J, Wang Y, Zeng L, Wu Y, Deng J, et al. (2014) Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer. Cancer Cell 25:210-25.
34. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, et al. (2014) AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 33:1316-24.
35. Shi J, Wang E, Zuber J, Rappaport A, Taylor M, et al. (2013) The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLLAF9; Nras(G12D) acute myeloid leukemia. Oncogene 32:930-8.
36. Yuan W, Wu T, Fu H, Dai C, Wu H, et al. (2012) Dense chromatin activates polycomb repressive complex 2 to regulate H3 lysine 27 methylation. Science 337:971-5.
37. Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, et al. (2011) Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer 10:40.
38. Fan Y, Shen B, Tan M, Mu X, Qin Y, et al. (2014) TGF-beta-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin Cancer Res 20:1531-41.
39. Zhang X, Chen X, Lin J, Lwin T, Wright G, et al. (2012) Myc represses miR- 15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 31:3002-8.
40. Buurman R, Gurlevik E, Schaffer V, Eilers M, Sandbothe M, et al. (2012) Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 143:811- 20.e1-15.
41. Yuan JH, Yang F, Chen BF, Lu Z, Huo XS, et al. (2011) The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology 54:2025-35.
42. Giudice FS, Pinto DS Jr, Nor JE, Squarize CH, Castilho RM (2013) Inhibition of histone deacetylase impacts cancer stem cells and induces epithelialmesenchyme transition of head and neck cancer. PLoS One 8:e58672.
43. Zeng SS, Yamashita T, Kondo M, Nio K, Hayashi T, et al. (2014) The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma. J Hepatol 60:127-34.
44. Labisso WL, Wirth M, Stojanovic N, Stauber RH, Schnieke A, et al. (2012) MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle 11:1593-602.
45. Zhao S, Venkatasubbarao K, Li S, Freeman JW (2003) Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells. Cancer Res 63:2624-30.
46. You JS, Kang JK, Lee EK, Lee JC, Lee SH, et al. (2008) Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene 27:1376-86.
47. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, et al. (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45: 495-528.